Stats

Summary

Flexion Therapeutics Inc is a development stage specialty pharmaceutical company. The Company is engaged in the development and commercialization of novel, long-acting, injectable pain therapies including; anti-inflammatory and analgesic therapies.

Flexion Therapeutics nabs new patent in U.S.

The USPTO has issued Flexion Therapeutics' (NASDAQ: FLXN ) patent number 10,301,645 for FX201, the company's gene therapy product candidate to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist (IL-1Ra), whenever inflammation is present within the j… read more...

Flexion Therapeutics nabs new patent in U.S.

via: SeekingAlpha at 2019-06-05 04:44:24:000

The USPTO has issued Flexion Therapeutics' (NASDAQ: FLXN ) patent number 10,301,645 for FX201, the company's gene therapy product candidate to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist (IL-1Ra), whenever inflammation is present within the j… read more...

Flexion Therapeutics nabs new patent in U.S.

via: SeekingAlpha at 2019-06-05 04:44:24:000

The USPTO has issued Flexion Therapeutics' (NASDAQ: FLXN ) patent number 10,301,645 for FX201, the company's gene therapy product candidate to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist (IL-1Ra), whenever inflammation is present within the j… read more...

Flexion Therapeutics: The Bottom Could Now Be In

via: SeekingAlpha at 2019-05-15 08:09:01:000

"How easy it is for so many of us today to be undoubtedly full of information yet fully deprived of accurate information." - Criss Jami One biotech stock that has held up very well during the recent turbulence of the market is Flexion Therapeutics ( FLXN ) . The stock was up over 15% last… read more...

Flexion Therapeutics: The Bottom Could Now Be In

via: SeekingAlpha at 2019-05-15 08:09:01:000

"How easy it is for so many of us today to be undoubtedly full of information yet fully deprived of accurate information." - Criss Jami One biotech stock that has held up very well during the recent turbulence of the market is Flexion Therapeutics ( FLXN ) . The stock was up over 15% last… read more...

Flexion Therapeutics: The Bottom Could Now Be In

via: SeekingAlpha at 2019-05-15 08:09:01:000

"How easy it is for so many of us today to be undoubtedly full of information yet fully deprived of accurate information." - Criss Jami One biotech stock that has held up very well during the recent turbulence of the market is Flexion Therapeutics ( FLXN ) . The stock was up over 15% last… read more...

Flexion up 14% premarket on Zilretta ramp

via: SeekingAlpha at 2019-05-09 05:03:42:000

Flexion Therapeutics (NASDAQ: FLXN ) is up 14% premarket on light volume on the heels of its Q1 report released after the close yesterday. More news on: Flexion Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Flexion up 14% premarket on Zilretta ramp

via: SeekingAlpha at 2019-05-09 05:03:42:000

Flexion Therapeutics (NASDAQ: FLXN ) is up 14% premarket on light volume on the heels of its Q1 report released after the close yesterday. More news on: Flexion Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Flexion up 14% premarket on Zilretta ramp

via: SeekingAlpha at 2019-05-09 05:03:42:000

Flexion Therapeutics (NASDAQ: FLXN ) is up 14% premarket on light volume on the heels of its Q1 report released after the close yesterday. More news on: Flexion Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Flexion up 14% premarket on Zilretta ramp

via: SeekingAlpha at 2019-05-09 05:03:42:000

Flexion Therapeutics (NASDAQ: FLXN ) is up 14% premarket on light volume on the heels of its Q1 report released after the close yesterday. More news on: Flexion Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Flexion Therapeutics: A Second (And More) Life For Zilretta

via: SeekingAlpha at 2019-04-22 22:59:58:000

Flexion Therapeutics ( FLXN ) got approval for Zilretta last year for osteoarthritis of the knee or OAK. Zilretta is the first extended-release corticosteroid approved by the FDA for the indication. Effective January 1, 2019, Zilretta has been assigned a separate reimbursement code called the … read more...

Flexion Therapeutics: A Second (And More) Life For Zilretta

via: SeekingAlpha at 2019-04-22 22:59:58:000

Flexion Therapeutics ( FLXN ) got approval for Zilretta last year for osteoarthritis of the knee or OAK. Zilretta is the first extended-release corticosteroid approved by the FDA for the indication. Effective January 1, 2019, Zilretta has been assigned a separate reimbursement code called the … read more...

Flexion Therapeutics: A Second (And More) Life For Zilretta

via: SeekingAlpha at 2019-04-22 22:59:58:000

Flexion Therapeutics ( FLXN ) got approval for Zilretta last year for osteoarthritis of the knee or OAK. Zilretta is the first extended-release corticosteroid approved by the FDA for the indication. Effective January 1, 2019, Zilretta has been assigned a separate reimbursement code called the … read more...

Flexion Therapeutics: A Second (And More) Life For Zilretta

via: SeekingAlpha at 2019-04-22 22:59:58:000

Flexion Therapeutics ( FLXN ) got approval for Zilretta last year for osteoarthritis of the knee or OAK. Zilretta is the first extended-release corticosteroid approved by the FDA for the indication. Effective January 1, 2019, Zilretta has been assigned a separate reimbursement code called the … read more...

Flexion Therapeutics: A Second (And More) Life For Zilretta

via: SeekingAlpha at 2019-04-22 22:59:58:000

Flexion Therapeutics ( FLXN ) got approval for Zilretta last year for osteoarthritis of the knee or OAK. Zilretta is the first extended-release corticosteroid approved by the FDA for the indication. Effective January 1, 2019, Zilretta has been assigned a separate reimbursement code called the … read more...

Stocks To Watch: Disney+ And Bank Majors Step Out

via: SeekingAlpha at 2019-04-06 04:39:00:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees a heavy dose of healthcare companies presenting at investor con… read more...

Flexion: Time To Join The Dance

via: SeekingAlpha at 2019-02-18 18:36:12:000

Flexion ( FLXN ) is in the process of establishing itself as a reliable revenue generator. I have been attracted to its potential and have been watching it for over a year. It is coming along nicely. I have been holding back on starting a position until it worked out kinks inherent in launchin… read more...

Flexion: Time To Join The Dance

via: SeekingAlpha at 2019-02-18 18:36:12:000

Flexion ( FLXN ) is in the process of establishing itself as a reliable revenue generator. I have been attracted to its potential and have been watching it for over a year. It is coming along nicely. I have been holding back on starting a position until it worked out kinks inherent in launchin… read more...

Flexion: Time To Join The Dance

via: SeekingAlpha at 2019-02-18 18:36:12:000

Flexion ( FLXN ) is in the process of establishing itself as a reliable revenue generator. I have been attracted to its potential and have been watching it for over a year. It is coming along nicely. I have been holding back on starting a position until it worked out kinks inherent in launchin… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Perception Vs. Reality

via: SeekingAlpha at 2018-12-03 11:13:12:000

Living with a loss is folly, taking a loss is wisdom. . . . Lewis Owen For years we have quoted Benjamin Graham's book, The Intelligent Investor, which Warren Buffet has said is the best book ever written on investing. The operative quote from said book is "The essence of portfolio manag… read more...

Perception Vs. Reality

via: SeekingAlpha at 2018-12-03 11:13:12:000

Living with a loss is folly, taking a loss is wisdom. . . . Lewis Owen For years we have quoted Benjamin Graham's book, The Intelligent Investor, which Warren Buffet has said is the best book ever written on investing. The operative quote from said book is "The essence of portfolio manag… read more...

Perception Vs. Reality

via: SeekingAlpha at 2018-12-03 11:13:12:000

Living with a loss is folly, taking a loss is wisdom. . . . Lewis Owen For years we have quoted Benjamin Graham's book, The Intelligent Investor, which Warren Buffet has said is the best book ever written on investing. The operative quote from said book is "The essence of portfolio manag… read more...

Perception Vs. Reality

via: SeekingAlpha at 2018-12-03 11:13:12:000

Living with a loss is folly, taking a loss is wisdom. . . . Lewis Owen For years we have quoted Benjamin Graham's book, The Intelligent Investor, which Warren Buffet has said is the best book ever written on investing. The operative quote from said book is "The essence of portfolio manag… read more...

Centrexion IPO: At Phase 3, But Don't Expect The Share Price To Go To The Moon

via: SeekingAlpha at 2018-11-13 13:23:49:000

With one product candidate at Phase 3 of development, a large amount of cash and a solid balance sheet, Centrexion Therapeutics ( CNTX ) may attract the attention of certain institutional investors. With that, a detailed assessment of the competitors shows that there are many companies that ar… read more...

Centrexion IPO: At Phase 3, But Don't Expect The Share Price To Go To The Moon

via: SeekingAlpha at 2018-11-13 13:23:49:000

With one product candidate at Phase 3 of development, a large amount of cash and a solid balance sheet, Centrexion Therapeutics ( CNTX ) may attract the attention of certain institutional investors. With that, a detailed assessment of the competitors shows that there are many companies that ar… read more...

Centrexion IPO: At Phase 3, But Don't Expect The Share Price To Go To The Moon

via: SeekingAlpha at 2018-11-13 13:23:49:000

With one product candidate at Phase 3 of development, a large amount of cash and a solid balance sheet, Centrexion Therapeutics ( CNTX ) may attract the attention of certain institutional investors. With that, a detailed assessment of the competitors shows that there are many companies that ar… read more...

Centrexion IPO: At Phase 3, But Don't Expect The Share Price To Go To The Moon

via: SeekingAlpha at 2018-11-13 13:23:49:000

With one product candidate at Phase 3 of development, a large amount of cash and a solid balance sheet, Centrexion Therapeutics ( CNTX ) may attract the attention of certain institutional investors. With that, a detailed assessment of the competitors shows that there are many companies that ar… read more...

Flexion Therapeutics: Reversal In Sentiment?

via: SeekingAlpha at 2018-11-09 14:39:25:000

We no longer live life. We consume it ." - Vicki Robin Insiders and Biotech Forum model portfolio holding Flexion Therapeutics ( FLXN ) was one of the markets big winners in the market on Thursday. The almost 20% rise in the stock was triggered by better than expected Q3 results and som… read more...

Flexion Therapeutics: Reversal In Sentiment?

via: SeekingAlpha at 2018-11-09 14:39:25:000

We no longer live life. We consume it ." - Vicki Robin Insiders and Biotech Forum model portfolio holding Flexion Therapeutics ( FLXN ) was one of the markets big winners in the market on Thursday. The almost 20% rise in the stock was triggered by better than expected Q3 results and som… read more...

Flexion Therapeutics: Reversal In Sentiment?

via: SeekingAlpha at 2018-11-09 14:39:25:000

We no longer live life. We consume it ." - Vicki Robin Insiders and Biotech Forum model portfolio holding Flexion Therapeutics ( FLXN ) was one of the markets big winners in the market on Thursday. The almost 20% rise in the stock was triggered by better than expected Q3 results and som… read more...

Flexion Therapeutics: Reversal In Sentiment?

via: SeekingAlpha at 2018-11-09 14:39:25:000

We no longer live life. We consume it ." - Vicki Robin Insiders and Biotech Forum model portfolio holding Flexion Therapeutics ( FLXN ) was one of the markets big winners in the market on Thursday. The almost 20% rise in the stock was triggered by better than expected Q3 results and som… read more...

Flexion up 19% after Q3 beat, Zilretta commercial progress

via: SeekingAlpha at 2018-11-08 11:21:50:000

Flexion Therapeutics ( FLXN +18.7% ) is up on average volume following its Q3 report released after the close yesterday. Highlights: More news on: Flexion Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Centrexion Therapeutics Seeks $75 Million In Proposed IPO

via: SeekingAlpha at 2018-11-05 13:56:42:000

Quick Take Centrexion Therapeutics ( CNTX ) intends to raise $75 million from the sale of its common stock in an IPO. The company is advancing a pipeline of next-generation pain treatment candidates. CNTX has a top-tier CEO, is a mid-stage firm with promising trial results to-date, and h… read more...

Centrexion Therapeutics Seeks $75 Million In Proposed IPO

via: SeekingAlpha at 2018-11-05 13:56:42:000

Quick Take Centrexion Therapeutics ( CNTX ) intends to raise $75 million from the sale of its common stock in an IPO. The company is advancing a pipeline of next-generation pain treatment candidates. CNTX has a top-tier CEO, is a mid-stage firm with promising trial results to-date, and h… read more...

Centrexion Therapeutics Begins U.S. IPO Effort

via: SeekingAlpha at 2018-10-25 16:11:14:000

Quick Take Centrexion Therapeutics ( CNTX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing medication for moderate to severe chronic pain. CNTX is in Phase 3 trials for three programs for its lead ca… read more...

Centrexion Therapeutics Begins U.S. IPO Effort

via: SeekingAlpha at 2018-10-25 16:11:14:000

Quick Take Centrexion Therapeutics ( CNTX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing medication for moderate to severe chronic pain. CNTX is in Phase 3 trials for three programs for its lead ca… read more...

Centrexion Therapeutics Begins U.S. IPO Effort

via: SeekingAlpha at 2018-10-25 16:11:14:000

Quick Take Centrexion Therapeutics ( CNTX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing medication for moderate to severe chronic pain. CNTX is in Phase 3 trials for three programs for its lead ca… read more...

Flexion Is Flexible With The Data, Rigid With The Price

via: SeekingAlpha at 2018-10-17 09:30:00:000

Summary Flexion ( FLXN ) has developed and won approval for ZILRETTA (Triamcinolone acetonide extended-release, TA-ER) for osteoarthritis-related knee pain; Zilretta is Flexions only approved product. Outside of Zilretta, the pipeline for Flexion is essentially barren; the company&… read more...

Flexion Is Flexible With The Data, Rigid With The Price

via: SeekingAlpha at 2018-10-17 09:30:00:000

Summary Flexion ( FLXN ) has developed and won approval for ZILRETTA (Triamcinolone acetonide extended-release, TA-ER) for osteoarthritis-related knee pain; Zilretta is Flexions only approved product. Outside of Zilretta, the pipeline for Flexion is essentially barren; the company&… read more...

Flexion Is Flexible With The Data, Rigid With The Price

via: SeekingAlpha at 2018-10-17 09:30:00:000

Summary Flexion ( FLXN ) has developed and won approval for ZILRETTA (Triamcinolone acetonide extended-release, TA-ER) for osteoarthritis-related knee pain; Zilretta is Flexions only approved product. Outside of Zilretta, the pipeline for Flexion is essentially barren; the company&… read more...

Axsome Therapeutics: Several Candidates At Phase 3

via: SeekingAlpha at 2018-10-11 12:11:55:000

With several candidates at Phase 3 of development, Axsome Therapeutics, Inc. (AXSM) should interest investors. In addition, the target market seems quite large, which is also ideal. With that, the company trades at an overvalued 10x book value per share, which seems like an overvalued level … read more...

Axsome Therapeutics: Several Candidates At Phase 3

via: SeekingAlpha at 2018-10-11 12:11:55:000

With several candidates at Phase 3 of development, Axsome Therapeutics, Inc. (AXSM) should interest investors. In addition, the target market seems quite large, which is also ideal. With that, the company trades at an overvalued 10x book value per share, which seems like an overvalued level … read more...

Axsome Therapeutics: Several Candidates At Phase 3

via: SeekingAlpha at 2018-10-11 12:11:55:000

With several candidates at Phase 3 of development, Axsome Therapeutics, Inc. (AXSM) should interest investors. In addition, the target market seems quite large, which is also ideal. With that, the company trades at an overvalued 10x book value per share, which seems like an overvalued level … read more...

Flexion: Waiting And Watching

via: SeekingAlpha at 2018-08-22 05:22:24:000

This posting focuses on Flexion Therapeutics' (FLXN) Zilretta launch as a therapy for osteoarthritis knee pain , now exiting its second full post-launch quarter. I conclude that Zilretta is likely to continue to be more of a financial burden than a contributor for the balance of 2018. Accordi… read more...

Flexion: Waiting And Watching

via: SeekingAlpha at 2018-08-22 05:22:24:000

This posting focuses on Flexion Therapeutics' (FLXN) Zilretta launch as a therapy for osteoarthritis knee pain , now exiting its second full post-launch quarter. I conclude that Zilretta is likely to continue to be more of a financial burden than a contributor for the balance of 2018. Accordi… read more...

Flexion: Waiting And Watching

via: SeekingAlpha at 2018-08-22 05:22:24:000

This posting focuses on Flexion Therapeutics' (FLXN) Zilretta launch as a therapy for osteoarthritis knee pain , now exiting its second full post-launch quarter. I conclude that Zilretta is likely to continue to be more of a financial burden than a contributor for the balance of 2018. Accordi… read more...

Flexion: Waiting And Watching

via: SeekingAlpha at 2018-08-22 05:22:24:000

This posting focuses on Flexion Therapeutics' (FLXN) Zilretta launch as a therapy for osteoarthritis knee pain , now exiting its second full post-launch quarter. I conclude that Zilretta is likely to continue to be more of a financial burden than a contributor for the balance of 2018. Accordi… read more...

FDA and NIH to loosen oversight of gene therapy development

via: SeekingAlpha at 2018-08-16 09:47:09:000

Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study… read more...

FDA and NIH to loosen oversight of gene therapy development

via: SeekingAlpha at 2018-08-16 09:47:09:000

Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study… read more...

FDA and NIH to loosen oversight of gene therapy development

via: SeekingAlpha at 2018-08-16 09:47:09:000

Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study… read more...

FDA and NIH to loosen oversight of gene therapy development

via: SeekingAlpha at 2018-08-16 09:47:09:000

Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study… read more...

FDA and NIH to loosen oversight of gene therapy development

via: SeekingAlpha at 2018-08-16 09:47:09:000

Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study… read more...

Permanent reimbursement for Flexion's Zilretta established in U.S.

via: SeekingAlpha at 2018-05-04 08:15:58:000

Flexion Therapeutics (NASDAQ: FLXN ) announces that the U.S. Centers for Medicare and Medicaid Services (CMS) has established a permanent reimbursement code for ZILRETTA (triamcinolone acetonide extended-release injectable suspension) that will go into effect January 1, 2019. More news o… read more...

Permanent reimbursement for Flexion&apos;s Zilretta established in U.S.

via: SeekingAlpha at 2018-05-04 08:15:58:000

Flexion Therapeutics (NASDAQ: FLXN ) announces that the U.S. Centers for Medicare and Medicaid Services (CMS) has established a permanent reimbursement code for ZILRETTA (triamcinolone acetonide extended-release injectable suspension) that will go into effect January 1, 2019. More news o… read more...

Permanent reimbursement for Flexion's Zilretta established in U.S.

via: SeekingAlpha at 2018-05-04 08:15:58:000

Flexion Therapeutics (NASDAQ: FLXN ) announces that the U.S. Centers for Medicare and Medicaid Services (CMS) has established a permanent reimbursement code for ZILRETTA (triamcinolone acetonide extended-release injectable suspension) that will go into effect January 1, 2019. More news o… read more...

2 Attractive Biotech Stocks To Buy Now

via: SeekingAlpha at 2018-05-02 10:25:19:000

T he Guide says there is an art to flying", said Ford, "or rather a knack. The knack lies in learning how to throw yourself at the ground and miss . Douglas Adams, Life, the Universe and Everything Today, we profiled two biotech stocks that we believe are set up to do w… read more...

2 Attractive Biotech Stocks To Buy Now

via: SeekingAlpha at 2018-05-02 10:25:19:000

T he Guide says there is an art to flying", said Ford, "or rather a knack. The knack lies in learning how to throw yourself at the ground and miss . Douglas Adams, Life, the Universe and Everything Today, we profiled two biotech stocks that we believe are set up to do w… read more...

2 Attractive Biotech Stocks To Buy Now

via: SeekingAlpha at 2018-05-02 10:25:19:000

T he Guide says there is an art to flying", said Ford, "or rather a knack. The knack lies in learning how to throw yourself at the ground and miss . Douglas Adams, Life, the Universe and Everything Today, we profiled two biotech stocks that we believe are set up to do w… read more...

Flexion up 2% on new Zilretta data in OAK

via: SeekingAlpha at 2018-04-26 11:12:09:000

Flexion Therapeutics ( FLXN +2.3% ) is up, albeit on light volume, on the heels of its announcement of additional data from the open-label Phase 3b study evaluating ZILRETTA (triamcinolone acetonide) in patients with osteoarthritis of the knee (OAK). The results will be presented tomorro… read more...

Flexion up 2% on new Zilretta data in OAK

via: SeekingAlpha at 2018-04-26 11:12:09:000

Flexion Therapeutics ( FLXN +2.3% ) is up, albeit on light volume, on the heels of its announcement of additional data from the open-label Phase 3b study evaluating ZILRETTA (triamcinolone acetonide) in patients with osteoarthritis of the knee (OAK). The results will be presented tomorro… read more...

2 Small Biotechs To Buy On This Dip

via: SeekingAlpha at 2018-02-08 16:14:50:000

Those who make conversations impossible, make escalation inevitable . Stefan Molyneux It has been a wild wide so far for investors so far in the month of February. Each day of the month seem to have triggered huge intra-day swings within equities. Stocks have given up mo… read more...

2 Small Biotechs To Buy On This Dip

via: SeekingAlpha at 2018-02-08 16:14:50:000

Those who make conversations impossible, make escalation inevitable . Stefan Molyneux It has been a wild wide so far for investors so far in the month of February. Each day of the month seem to have triggered huge intra-day swings within equities. Stocks have given up mo… read more...

2 Small Biotechs To Buy On This Dip

via: SeekingAlpha at 2018-02-08 16:14:50:000

Those who make conversations impossible, make escalation inevitable . Stefan Molyneux It has been a wild wide so far for investors so far in the month of February. Each day of the month seem to have triggered huge intra-day swings within equities. Stocks have given up mo… read more...

Flexion: Ready To Rumble (Almost)

via: SeekingAlpha at 2018-01-11 05:29:44:000

Flexion ( FLXN ) offers relief to weary folks whose knees are killing them. Its stock is poised to do the same for its investors' portfolios; there is just one key detail needing resolution. Investors interested in the Flexion story need to hold back until they get some clarity on this one iss… read more...

Stocks to watch next week

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. More news on: Apple Inc., Amazon.com, Inc., Intel Corporation, Tech stocks news, … read more...

pSivida's Encouraging Knee Osteoarthritis Data

via: SeekingAlpha at 2017-12-15 13:48:28:000

pSivida Corp. (NASDAQ: PSDV ), a specialty pharmaceutical company specializing in sustained release drug delivery products for diseases of the eye, recently released promising data from their knee osteoarthritis ((OA)) Phase 1 trial. This is highly encouraging, as it proves that the company's … read more...

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Neurocrine Biosciences Today we will d… read more...

Solitude is fine but you need someone to tell that solitude is fine . - Honore De Balzac The biotech sector Monday added slightly to its gains from Friday after last week's decline on poor earning results from industry stalwarts like Celgene ( CELG ) . Once again small caps in th… read more...